Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.45 |
| ▸ | BRD2 | P25440 | 6/20 | 0.45 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21847207 | 0.94 | BRD4 (0.53) | BRD4BRD2DNERADORA3TSPO | |
| SCHEMBL8317711 | 0.94 | BRD4 (0.44) | BRD4BRD2DNERADORA3TSPO | |
| SCHEMBL8316217 | 0.92 | BRD4 (0.42) | BRD4BRD2BRD3BRDT | |
| SCHEMBL8320587 | 0.91 | BRD4 (0.45) | BRD4BRD2DNERADORA3TSPO | |
| SCHEMBL21847101 | 0.88 | BRD4 (0.41) | BRD4BRD2ADORA3TSPOBRD3 | |
| SCHEMBL8320915 | 0.88 | BRD4 (0.52) | BRD4BRD2DNERADORA3TSPO | |
| SCHEMBL21847116 | 0.87 | BRD4 (0.46) | BRD4BRD2DNERADORA3TSPO | |
| SCHEMBL21847270 | 0.87 | BRD4 (0.50) | BRD4BRD2ADORA3TSPOBRD3 | |
| SCHEMBL21847191 | 0.86 | BRD4 (0.47) | BRD4BRD2DNERADORA3TSPO | |
| SCHEMBL21914542 | 0.85 | BRD4 (0.42) | BRD4BRD2DNERADORA3TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | claimed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3640253-A1 | 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI Pharmaceutical Corporation (JP) | 2020-04-22 | — | — | EP | disclosed |
| EP-3640253-A1 | 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI Pharmaceutical Corporation (JP) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | BRD4, BRD3, BRD2 | BRD4 1/4885BRD2 3/4885DNER 1913/4885 |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | BRD4, BRD3, BRD2 | BRD4 1/4885BRD2 3/4885DNER 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.